Uncategorized

Epstein-Barr virus (EBV) infection is widespread among adults, yet there is no standard treatment for EBV-positive hematologic malignancies, leading to poor patient outcomes. At the 29th Annual Meeting of the European Hematology Association (EHA), Professor Chunrui Li from Tongji Hospital of Huazhong University of Science and Technology presented the results of her team’s Phase I exploratory trial of the KSD-101 dendritic cell vaccine in treating EBV-related hematologic malignancies. This study brings new hope for treating these diseases. Oncology Frontier-Hematology Frontier interviewed Professor Li to delve into this innovative research and discuss the potential impact of KSD-101 on the future of hematologic malignancy treatment.

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). At the 29th European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, from June 13 to 16, 2024, notable advancements were made in MPN research. Oncology Frontier-Hematology Frontier invited Professor Minghui Duan from the Department of Hematology, Peking Union Medical College Hospital, to introduce and provide an in-depth review of two significant studies on myelofibrosis treatment. We hope Professor Duan's insights will help us understand the research progress in this field and provide important references for future research and treatment.

To help clinical hepatologists broaden their horizons and enrich their practical experience, the Hepatology Digest journal has invited Professor Shanhong Tang's team from the Department of Gastroenterology at General Hospital of Western Theater Command to create the "Liver Challenging Cases" column. This column compiles classic cases encountered by Professor Tang’s team over years of clinical practice and will periodically include complex or rare cases from renowned academic journals. The focus is on elucidating diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical insights for colleagues.

In this enlightening interview, Professor Xiaofan Zhu discusses cutting-edge methods for MRD detection and risk stratification in pediatric AML, highlighting the promising role of ctDNA testing.

✨ Ordinary Yet Extraordinary: The Diverse Roles of Doctors in the Fight Against Disease 🌟 - An Interview with Professor Sheng Yan

Uveal melanoma (UM) is a severe ocular malignant tumor that threatens patients' vision and survival. Despite some progress in treatment methods in recent years, the survival rate of patients has not significantly improved due to the lack of effective drugs, especially those that inhibit metastasis. At the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, several rapid oral reports focused on the challenges of UM treatment and presented the latest research findings. Oncology Frontier has compiled relevant studies for readers.

In this "Man Talks Breast Cancer: ASCO Special," Professor Man Li's team from The Second Affiliated Hospital of Dalian Medical University has selected the latest ASCO studies on HR+ advanced breast cancer, covering topics such as cross-line treatment with CDK4/6 inhibitors, novel ADCs combined with ICIs, and comparing CDK4/6 inhibitors + ET with chemotherapy in premenopausal women. These can provide more valuable insights for clinical practice.

Brain metastasis from breast cancer has a high incidence, second only to lung cancer . Previous studies have shown that patients with brain metastases have poorer survival compared to those without brain metastases, with HER2-negative breast cancer brain metastasis patients having an even worse prognosis . Due to the blood-brain barrier (BBB), many drug treatments have limited intracranial objective response rates (ORR). Utidelone, a novel microtubule inhibitor developed in China, has shown potential for treating brain metastases due to its unique physicochemical properties that allow it to penetrate the BBB. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, a multicenter phase II study led by Professor Min Yan from Henan Cancer Hospital was selected for presentation. This study explored the efficacy and safety of utidelone combined with bevacizumab in treating HER2-negative breast cancer brain metastases. "Oncology Frontier" invited Professor Min Yan to discuss the progress in treating breast cancer brain metastases, the study design and findings, and future perspectives.

The efficacy of CAR-T therapy in B-cell lymphoma is increasingly recognized, and its real-world application is expanding. However, patients with high tumor burden face a high incidence of cytokine release syndrome (CRS) and poor outcomes, leading to high treatment-related mortality. There is an urgent need for effective bridging therapies to reduce CRS incidence and improve remission rates in relapsed/refractory B-cell lymphoma patients. From June 13-16, 2024, the 29th European Hematology Association (EHA) Annual Meeting will take place. Dr.  Rui Liu, head of the research team of Professors Xiaoyan Ke and Kai Hu from Beijing Gaobo Hospital, will present a poster titled “VENETOCLAX AND BTK INHIBITORS BASED CHEMOTHERAPY IS A POTENTIAL EFFECTIVE CAR-T BRIDGING THERAPY IN R/R B-NHL,” offering new insights into bridging therapies before CAR-T for relapsed/refractory B-cell lymphoma.